We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




POC Glucose Meter Evaluated for Neonatal Intensive Care

By LabMedica International staff writers
Posted on 17 Oct 2013
The monitoring of blood glucose in neonatal intensive care unit (NICU) patients is important in maintaining normoglycemia and reducing the risk of hypoglycemia. More...


Point-of-care testing (POCT) glucose meters provide short turnaround times but some have been reported to be affected by hematocrit interference and other biochemical or biological substances in their accuracy and performance.

Scientists at the Medical University of Vienna (Austria) tested 159 heparinized whole blood samples from NICU patients obtained for blood gas analysis. Accuracy (bias) of a new meter and analytical interferences were evaluated by comparing the results of the meter with the results of the blood gas analyzer routinely used for glucose measurements in this NICU setting.

Routine glucose measurements were performed at each hospital site using blood gas analyzers ABL 700 and ABL 835 (Radiometer Medical ApS, Copenhagen, Denmark). The blood gas analyzers were considered the appropriate reference method for comparing the performance of StatStrip Glucose POCT (Nova Biomedical; Waltham, MA, USA).

The results of glucose values covered the range of hypoglycemia to hyperglycemia, with glucose concentrations ranging from 13 mg/dL to 389 mg/dL. The results obtained for the Nova StatStrip Glucose POCT were not affected by the level of hematocrit, by sample pH or by medication. In the two children’s hospitals where the study was performed, the NICU patient population demonstrated a wide range of hematocrit levels even beyond the levels of the ranges claimed as not showing interferences in the product labeling of other glucose meters.

The authors concluded that the accuracy of the NOVA StatStrip Glucose meter results was not influenced by the varying hematocrit levels in the NICU patients, which validates the performance of the hematocrit correction that is in-built into the design of StatStrip Glucose. The StatStrip meter showed good clinical accuracy and performance for measuring and monitoring glucose levels in NICU patients, with special respect to preterm infants, and therefore can act as a perfect alternative to a blood gas analyzer for measuring blood glucose in NICU patients. The study was published on September 1, 2013, in the journal Clinical Chemistry and Laboratory Medicine.

Related Links:
Medical University of Vienna
Radiometer Medical ApS
Nova Biomedical


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
Manual Pipetting Aid
Pipette Controllers macro
New
Drug Testing Assays
Atellica DT 250 Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.